HI-Bio
Janet L. is a Senior Director of Finance at HI-Bio, bringing with their a wealth of experience in financial planning and analysis from previous roles at companies such as Amunix Pharmaceuticals, MyoKardia, and Gilead Sciences. With a background in finance and a degree in Drug Development Process from UC Berkeley Extension, Janet L. is well-versed in the pharmaceutical industry and is a valuable asset to any team Janet is a part of.
This person is not in any teams
HI-Bio
HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.